Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/222915
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer |
Autor: | Nieto-Jiménez, Cristina; Galán-Moya, Eva María; Corrales-Sánchez, Verónica; Noblejas-López, María del Mar; Burgos, Miguel; Domingo, Beatriz; Montero, Juan Carlos CSIC ORCID; Gómez-Juárez, Mónica; Picazo-Martinez, Maria Granada; Esparís-Ogando, Azucena CSIC ORCID ; Pandiella, Atanasio CSIC ORCID CVN ; Ocaña, Alberto | Palabras clave: | Cancer resistance Volasertib Epigenetics |
Fecha de publicación: | 2020 | Editor: | Elsevier | Citación: | Cancer Letters 491: 50-59 (2020) | Resumen: | The inhibition of bromo- and extraterminal domains (BET) has shown an anti-proliferative effect in triple negative breast cancer (TNBC). In this article we explore mechanisms of resistance to BET inhibitors (BETi) in TNBC, with the aim of identifying novel ways to overcome such resistance. Two cellular models of acquired resistance to the BET inhibitor JQ1 were generated using a pulsed treatment strategy. MTT, colony formation, and cytometry assays revealed that BETi-resistant cells were particularly sensitive to PLK1 inhibition. Targeting of the latter reduced cell proliferation, especially in resistant cultures. Quantitative PCR analysis of a panel of mitotic kinases uncovered an increased expression of AURKA, TTK, and PLK1, confirmed by Western blot. Only pharmacological inhibition of PLK1 showed anti-proliferative activity on resistant cells, provoking G2/M arrest, increasing expression levels of cyclin B, pH3 and phosphorylation of Bcl-2 proteins, changes that were accompanied by induction of caspase-dependent apoptosis. JQ1-resistant cells orthotopically xenografted into the mammary fat pad of mice led to tumours that retained JQ1-resistance. Administration of the PLK1 inhibitor volasertib resulted in tumour regression. These findings open avenues to explore the future use of PLK1 inhibitors in the clinical setting of BETi-resistant patients. | Versión del editor: | https://doi.org/10.1016/j.canlet.2020.06.020 | URI: | http://hdl.handle.net/10261/222915 | DOI: | 10.1016/j.canlet.2020.06.020 | ISSN: | 0304-3835 |
Aparece en las colecciones: | (IBMCC) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
inhibitcance.pdf | 5,25 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
11
checked on 20-mar-2024
WEB OF SCIENCETM
Citations
13
checked on 15-feb-2024
Page view(s)
139
checked on 19-abr-2024
Download(s)
197
checked on 19-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons